Teleflex Incorporated (NYSE:TFX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Teleflex Incorporated (NYSE:TFX) have earned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $267.50.

A number of equities research analysts have recently weighed in on the stock. Truist Financial reduced their price objective on shares of Teleflex from $270.00 to $265.00 and set a “hold” rating on the stock in a report on Friday, February 23rd. JMP Securities restated a “market outperform” rating and issued a $285.00 price objective on shares of Teleflex in a report on Friday, February 23rd. Royal Bank of Canada reduced their price objective on shares of Teleflex from $272.00 to $265.00 and set an “outperform” rating on the stock in a report on Friday, February 23rd. Finally, StockNews.com lowered shares of Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, February 23rd.

Teleflex Price Performance

Teleflex stock opened at $207.38 on Friday. The firm has a market cap of $9.77 billion, a PE ratio of 27.54, a price-to-earnings-growth ratio of 2.01 and a beta of 1.11. Teleflex has a 52-week low of $177.63 and a 52-week high of $276.43. The company has a quick ratio of 1.29, a current ratio of 2.32 and a debt-to-equity ratio of 0.39. The company’s 50 day moving average is $226.40 and its two-hundred day moving average is $225.08.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $3.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.26 by $0.12. Teleflex had a net margin of 11.98% and a return on equity of 14.98%. The business had revenue of $773.90 million for the quarter, compared to analyst estimates of $769.01 million. During the same period last year, the business earned $3.52 EPS. The company’s revenue was up 2.1% on a year-over-year basis. On average, research analysts expect that Teleflex will post 13.73 EPS for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.66%. The ex-dividend date was Thursday, February 29th. Teleflex’s payout ratio is currently 18.06%.

Insiders Place Their Bets

In other Teleflex news, VP Cameron P. Hicks sold 7,401 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the transaction, the vice president now directly owns 10,050 shares of the company’s stock, valued at approximately $2,261,250. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.43% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TFX. Allworth Financial LP boosted its holdings in shares of Teleflex by 332.3% in the third quarter. Allworth Financial LP now owns 134 shares of the medical technology company’s stock valued at $26,000 after acquiring an additional 103 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Teleflex in the third quarter valued at about $27,000. Covestor Ltd raised its position in Teleflex by 305.6% during the third quarter. Covestor Ltd now owns 146 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 110 shares during the last quarter. Riverview Trust Co acquired a new position in Teleflex during the first quarter worth about $31,000. Finally, Lindbrook Capital LLC raised its position in Teleflex by 75.3% during the fourth quarter. Lindbrook Capital LLC now owns 135 shares of the medical technology company’s stock worth $34,000 after acquiring an additional 58 shares during the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.